|
1) Nakao S, Feng X, Sugimori C. Immune pathophysiology of aplastic anemia. Int J Hematol. 2005; 82: 196-200
|
|
|
|
2) Wang H, Chuhjo T, Yasue S, et al. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood. 2002; 100: 3897-902
|
|
|
|
|
|
3) Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006; 107: 1308-14
|
|
|
|
|
|
4) Sugimori C, Yamazaki H, Feng X, et al. Roles of DRB1＊1501 and DRB1＊1502 in the pathogenesis of aplastic anemia. Exp Hematol. 2007; 35: 13-20
|
|
|
|
|
|
5) Feng X, Chuhjo T, Sugimori C, et al. Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood. 2004; 104: 2425-31
|
|
|
|
|
|
6) Takamatsu H, Feng X, Chuhjo T, et al. Specific antibodies to moesin, a membrane-cytoskeleton linker protein, are frequently detected in patients with acquired aplastic anemia. Blood. 2007; 109: 2514-20
|
|
|
|
|
|
7) Kusumoto S, Jinnai I, Matsuda A, et al. Bone marrow patterns in patients with aplastic anaemia and myelodysplastic syndrome: observations with magnetic resonance imaging. Eur J Haematol. 1997; 59: 155-61
|
|
|
|
|
|
8) Zeng W, Nakao S, Takamatsu H, et al. Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. Blood. 1999; 93: 3008-16
|
|
|
|
|
|
9) Nakao S, Takami A, Takamatsu H, et al. Isolation of a T-cell clone showing HLA-DRB1＊0405- restricted cytotoxicity for hematopoietic cells in a patient with aplastic anemia. Blood. 1997; 89: 3691-9
|
|
|
|
|
|
10) Nakao S, Takamatsu H, Chuhjo T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood. 1994; 84: 4257-61
|
|
|
|
|
|
11) Yamaguchi H, Baerlocher GM, Lansdorp PM, et al. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood. 2003; 102: 916-8
|
|
|
|
|
|
12) Yamaguchi H, Calado RT, Ly H, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med. 2005; 352: 1413-24
|
|
|
|
|
|
13) Araten DJ, Nafa K, Pakdeesuwan K, et al. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci U S A. 1999; 96: 5209-14
|
|
|
|
|
|
14) Hu R, Mukhina GL, Piantadosi S, et al. PIG-A mutations in normal hematopoiesis. Blood. 2005; 105: 3848-54
|
|
|
|
|
|
15) Murakami Y, Kosaka H, Maeda Y, et al. Inefficient response of T lymphocytes to glycosylphosphatidylinositol anchor-negative cells: implications for paroxysmal nocturnal hemoglobinuria. Blood. 2002; 100: 4116-22
|
|
|
|
|
|
16) Ishiyama K, Chuhjo T, Wang H, et al. Polyclonal hematopoiesis maintained in patients with bone marrow failure harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood. 2003; 102: 1211-6
|
|
|
|
|
|
17) Maciejewski JP, Follmann D, Nakamura R, et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood. 2001; 98: 3513-9
|
|
|
|
|
|
18) Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood. 2003; 102: 3025-7
|
|
|
|
|
|
19) Hirano N, Butler MO, Von Bergwelt-Baildon MS, et al. Autoantibodies frequently detected in patients with aplastic anemia. Blood. 2003; 102: 4567-75
|
|
|
|
|